No connection

Search Results

CTEV vs EBS

CTEV
Claritev Corporation
BEARISH
Price
$23.81
Market Cap
$404.0M
Sector
Healthcare
AI Confidence
85%
EBS
Emergent BioSolutions Inc.
BEARISH
Price
$8.03
Market Cap
$414.7M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
CTEV
--
EBS
8.63
Forward P/E
CTEV
3.48
EBS
2.69
P/B Ratio
CTEV
-2.27
EBS
0.8
P/S Ratio
CTEV
0.42
EBS
0.56
EV/EBITDA
CTEV
9.35
EBS
3.8

Profitability

Gross Margin
CTEV
73.75%
EBS
49.44%
Operating Margin
CTEV
9.77%
EBS
-15.2%
Profit Margin
CTEV
-29.45%
EBS
7.08%
ROE
CTEV
--
EBS
10.46%
ROA
CTEV
1.12%
EBS
5.33%

Growth

Revenue Growth
CTEV
6.2%
EBS
-23.6%
Earnings Growth
CTEV
--
EBS
--

Financial Health

Debt/Equity
CTEV
--
EBS
1.12
Current Ratio
CTEV
0.86
EBS
5.01
Quick Ratio
CTEV
0.6
EBS
2.19

Dividends

Dividend Yield
CTEV
--
EBS
--
Payout Ratio
CTEV
0.0%
EBS
0.0%

AI Verdict

CTEV BEARISH

CTEV exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a negative Price-to-Book ratio of -2.27, indicating negative shareholder equity. While the company maintains strong gross margins (73.75%) and a low Price-to-Sales ratio (0.42), these are overshadowed by catastrophic earnings volatility and a 5-year price collapse of 91.9%. The current liquidity position is precarious with a current ratio of 0.86, suggesting an inability to cover short-term obligations. Despite bullish analyst targets, the deterministic data points to a high-risk value trap.

Strengths
Strong Gross Margin of 73.75%
Positive Operating Margin of 9.77%
Low Price-to-Sales ratio (0.42) suggesting undervaluation relative to revenue
Risks
Negative Book Value (P/B -2.27) indicating insolvency risk
Weak Piotroski F-Score (2/9) signaling deteriorating fundamental health
Liquidity risk with Current Ratio (0.86) and Quick Ratio (0.60) below 1.0
EBS BEARISH

EBS presents as a classic value trap, characterized by a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between its Graham Number ($14.48) and Intrinsic Value ($6.51). While the stock appears cheap on a P/E and P/S basis, this is offset by a severe revenue contraction of -23.6% YoY and negative operating margins (-15.20%). The combination of bearish insider sentiment, a 0/100 technical trend, and extreme earnings volatility suggests that the current price is not yet reflecting the full extent of the fundamental decay.

Strengths
Strong short-term liquidity with a Current Ratio of 5.01
Low valuation multiples (P/E 8.63, P/S 0.56)
Healthy Gross Margin of 49.44%
Risks
Significant revenue decline (-23.6% YoY and -24.04% Q/Q)
Negative operating margins indicating an unsustainable core business model
Bearish insider activity with consistent selling and zero buying

Compare Another Pair

CTEV vs EBS: Head-to-Head Comparison

This page compares Claritev Corporation (CTEV) and Emergent BioSolutions Inc. (EBS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile